98%
921
2 minutes
20
Sample multiplexing facilitates scRNA-seq by reducing costs and identifying artifacts such as cell doublets. However, universal and scalable sample barcoding strategies have not been described. We therefore developed MULTI-seq: multiplexing using lipid-tagged indices for single-cell and single-nucleus RNA sequencing. MULTI-seq reagents can barcode any cell type or nucleus from any species with an accessible plasma membrane. The method involves minimal sample processing, thereby preserving cell viability and endogenous gene expression patterns. When cells are classified into sample groups using MULTI-seq barcode abundances, data quality is improved through doublet identification and recovery of cells with low RNA content that would otherwise be discarded by standard quality-control workflows. We use MULTI-seq to track the dynamics of T-cell activation, perform a 96-plex perturbation experiment with primary human mammary epithelial cells and multiplex cryopreserved tumors and metastatic sites isolated from a patient-derived xenograft mouse model of triple-negative breast cancer.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6837808 | PMC |
http://dx.doi.org/10.1038/s41592-019-0433-8 | DOI Listing |
Anal Bioanal Chem
September 2025
GuangDong Engineering Technology Research Center of Antibody Drug and Immunoassay, Department of Biological Sciences and Biotechnology, College of Life Science and Technology, Jinan University, Guangzhou, 510632, China.
Illicit drug abuse poses a significant global threat to public health and social security, highlighting the urgent need for rapid, sensitive, and versatile detection technologies. To address the limitations of traditional chromatographic techniques-such as high costs and slow response times-and the drawbacks of conventional immunochromatographic sensors (ICS), including low sensitivity and non-intuitive signal outputs, a fluorescence-quenching ICS (FQICS) was developed. This sensor leverages fluorescence resonance energy transfer (FRET) between aggregation-induced emission fluorescent microspheres (AIEFMs) and gold nanoparticles (AuNPs).
View Article and Find Full Text PDFVox Sang
September 2025
Blood Group Genetics Laboratory, Irish Blood Transfusion Service, Dublin, Ireland.
Background And Objectives: The discovery of circulating fetal DNA in maternal plasma enabled non-invasive prenatal testing (NIPT) for targeted anti-D prophylaxis. In 2019, Ireland implemented an in-house test to guide this care. Here, we report 6 years of service.
View Article and Find Full Text PDFSci Justice
September 2025
School of Life Sciences, University of KwaZulu-Natal, Private Bag X54001, Westville, Durban 4000, South Africa. Electronic address:
A compound marker integrates two or more genetic markers into a single assay. The application of compound markers enhances the predictive accuracy of genetic testing by leveraging the strengths of different genetic variations while mitigating the limitations of individual markers. Compound markers include SNP-SNPs, SNP-STRs, DIP-SNPs, DIP-STRs, Multi-In/Dels, CpG-SNPs, CpG-STRs/CpG-In/Del, and Methylation-Microhaplotypes.
View Article and Find Full Text PDFCell Rep Methods
September 2025
Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland; Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland. Electronic address:
In cancer research, multiplexed imaging allows detailed characterization of the tumor microenvironment (TME) and its link to patient prognosis. The integrated immunoprofiling of large adaptive cancer patient cohorts (IMMUcan) consortium collects multi-modal imaging data from thousands of patients with cancer to perform broad molecular and cellular spatial profiling. Here, we describe and compare two workflows for multiplexed immunofluorescence (mIF) and imaging mass cytometry (IMC) developed within IMMUcan to enable the generation of standardized data for cancer tissue analysis.
View Article and Find Full Text PDFTransl Oncol
September 2025
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Department of Biomedical Sciences Cedars-Sinai Medical Center, Los Angeles, CA, USA. Electronic address:
Bladder cancer (BC) remains a common malignancy, with muscle-invasive bladder cancer (MIBC) comprising 20 % of cases and a poor 5-year survival rate of ∼50 %. While neoadjuvant chemotherapy (NAC) followed by radical cystectomy is the standard treatment for locally advanced disease, NAC is limited by toxicity and non-response in many patients. Predictive biomarkers are urgently needed to guide treatment decisions.
View Article and Find Full Text PDF